感染疾病治疗药物市场规模、份额、成长分析、按类型、治疗方法、地区 - 产业预测，2024-2031

2022年全球感染疾病药物市场规模估值为1,168亿美元，从2023年的1,217.1亿美元成长到2031年的1,691.4亿美元，预计在复合预测期内（2024-2031年）将持续成长。年增率为4.2%）。

全球医疗保健产业继续面临由病毒和细菌等多种病原体引起的感染疾病的巨大挑战。儘管诊断、治疗方法和疫苗接种等预防措施取得了进步，降低了死亡率，但这些疾病的復发仍然是一个重大的公共卫生问题。因此，由于感染率上升、早期诊断意识增强以及政府和私人组织研究经费的增加，感染疾病药物市场预计将显着成长。然而，先进的治疗方法价格昂贵，限制了许多患者的使用，并对市场扩张构成了挑战。此外，人们越来越偏爱价格实惠的学名药，这威胁到了控制感染疾病的品牌疗法的成长。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术进步
• 监管环境
• 案例研究

感染疾病治疗药物市场规模：按类型和复合年增长率（2024-2031）

• 市场概况
• HIV
• 肝炎
• 流感
• 结核
• 疟疾
• HPV

感染疾病治疗药物市场规模：依治疗方法及复合年增长率（2024-2031）

• 市场概况
• 抗生素
• 抗真菌药物
• 抗病毒药物
• 其他的

感染疾病治疗药物市场规模：依最终用户及复合年增长率（2024-2031）

• 市场概况
• 医院
• 诊所

感染疾病治疗药物市场规模：按地区及复合年增长率（2024-2031）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Gilead Sciences
• GlaxoSmithKline（GSK）
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson（Janssen Pharmaceuticals）
• BioCryst Pharmaceuticals Inc.
• Boehringer Ingelheim GmbH
• AbbVie Inc.
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb（BMS）
• Moderna, Inc.
• Regeneron Pharmaceuticals
• Vertex Pharmaceuticals
• Vir Biotechnology, Inc.
• Eli Lilly and Company
• Amgen Inc.

结论和建议

Global Infectious Disease Therapeutics Market size was valued at USD 116.8 billion in 2022 and is poised to grow from USD 121.71 billion in 2023 to USD 169.14 billion by 2031, growing at a CAGR of 4.2% during the forecast period (2024-2031).

The global healthcare sector continues to face immense challenges due to infectious diseases, which are triggered by a range of pathogens including viruses and bacteria. Despite progress in diagnostics, treatment methods, and preventive measures like vaccinations that have lowered mortality rates, the resurgence of these diseases remains a critical public health issue. Consequently, the infectious disease therapeutics market is poised for considerable growth, driven by rising infection rates, heightened awareness for early diagnosis, and increased funding for research from governmental and private entities. Nonetheless, the expensive nature of advanced treatments poses a challenge for market expansion, limiting access for many patients. Additionally, the growing preference for affordable generic medications threatens the growth of branded therapeutics aimed at combating infectious diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infectious Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Infectious Disease Therapeutics Market Segmental Analysis

Global Infectious Disease Therapeutics Market is segmented by type, treatment, end users and region. Based on type, the market is segmented into HIV, hepatitis, influenza, TB, malaria and HPV. Based on treatment, the market is segmented into antibacterial, antifungal drugs, antiviral drugs and others. Based on end users, the market is segmented into hospitals and clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Infectious Disease Therapeutics Market

The global infectious disease therapeutics market is likely to experience significant growth due to several driving factors. An increase in investment aimed at improving access to treatments for infectious diseases, along with strategic initiatives to raise awareness regarding both the treatments and diagnostics of these conditions, will contribute positively to market expansion. Furthermore, there has been a noticeable rise in clinical trial research dedicated to the development of innovative pharmaceutical solutions. Collectively, these elements are expected to propel the demand for infectious disease therapeutics, shaping a promising outlook for the market in the coming years.

Restraints in the Global Infectious Disease Therapeutics Market

The growth of the Global Infectious Disease Therapeutics market may be hindered by several factors, particularly the lack of awareness regarding available treatment options. In many developing nations, there is insufficient adoption of these therapies, compounded by limited reimbursement options for specific infectious diseases. This combination of inadequate understanding and accessibility can significantly restrain the market's expansion throughout the projected timeframe, as healthcare providers and patients may not fully utilize or access the innovative treatments necessary to combat these diseases effectively. Consequently, addressing these challenges is crucial for the market to reach its full potential in the coming years.

Market Trends of the Global Infectious Disease Therapeutics Market

The Global Infectious Disease Therapeutics market is witnessing significant growth, driven by the rising prevalence of malaria, particularly in developing regions such as India, Africa, and Southeast Asia. This surge is further fueled by increased research and development efforts from key pharmaceutical manufacturers and healthcare organizations aimed at advancing therapeutic options. Innovations in drug formulations and delivery methodologies, coupled with heightened awareness and funding for infectious disease management, are propelling the market forward. Additionally, strategic collaborations and partnerships in the healthcare sector are expected to enhance access to effective treatments, thereby shaping a robust market landscape in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Infectious Disease Therapeutics Market Size by Type & CAGR (2024-2031)

• Market Overview
• HIV
• Hepatitis
• Influenza
• TB
• Malaria
• HPV

Global Infectious Disease Therapeutics Market Size by Treatment & CAGR (2024-2031)

• Market Overview
• Antibacterial
• Antifungal Drugs
• Antiviral Drugs
• Others

Global Infectious Disease Therapeutics Market Size by End Users & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics

Global Infectious Disease Therapeutics Market Size & CAGR (2024-2031)

• North America (Type, Treatment, End Users)
  • USA
  • Canada
• Europe (Type, Treatment, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen Pharmaceuticals)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (BMS)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vir Biotechnology, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations